In terms of pharmacodynamics, previous studies have shown that Erjing Pills have the effect of inhibiting the expression of transmembrane receptor TLR4, and can downregulate the expression of NFκB p65, p-NFκB p65, IκBα, p-IκBα, in D-galactose combined with Aβ25–35 composite modeling-induced AD rats, and thus inhibit the content of downstream inflammatory factors and play a role in inhibiting neuroinflammation by suppressing TLR4/NFκB/NLRP3, and reducing the content of downstream inflammatory factors. Here, NFKBIA is linked to Alzheimer disease.